NextBioMedical Co Graham Number
The Graham Number of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 6,668.03 KRW.
Get this data via API
Financial Data API
Graham Number
6,668.03KRW
Last updated:
Graham Number of NextBioMedical Co is 2024 6,668.03 KRW. Graham Number of NextBioMedical Co was 2023 - KRW. It decreases by % lower compared to the previous year.
The NextBioMedical Co Graham Number history
| YEAR | Graham Number | YoY |
|---|---|---|
| 6,668.03KRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
NextBioMedical Co Stock analysis
What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings.
The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care.
NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about NextBioMedical Co stock
Graham Number of NextBioMedical Co is 6,668.03 KRW in 2024.
On Eulerpool you can find the complete historical development of Graham Number NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — NextBioMedical Co
All Key Metrics — NextBioMedical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth